---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-009364"
form_type: "8-K"
ticker: "NSPR"
cik: "0001433607"
company_name: "InspireMD, Inc."
filed_at: "2025-05-09T23:59:59+00:00"
generated_at: "2026-05-22T01:34:46.386835+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# InspireMD Q1 net loss widens to $0.22/sh; FDA approval of CGuard Prime expected Q3 2025

## Summary
- Revenue $1.529M (+1.2% YoY); net loss $11.166M ($0.22/sh) vs $7.032M loss ($0.21/sh) in Q1 2024.
- Operating expenses rose 52.5% to $11.752M on U.S. sales force build and CGuard Prime launch preparation.
- Cash and securities $26.086M at March 31, down from $34.637M at Dec 31, 2024.
- FDA PMA for CGuard Prime carotid stent system anticipated in Q3 2025; commercial team in place.

## SEC filing metadata
- accession: 0001641172-25-009364
- form_type: 8-K
- ticker: NSPR
- cik: 0001433607
- company_name: InspireMD, Inc.
- filed_at: 2025-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1433607/000164117225009364/0001641172-25-009364-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1433607/000164117225009364/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-009364
- JSON: https://secwatch.observer/filing/0001641172-25-009364.json
- Plain text: https://secwatch.observer/filing/0001641172-25-009364.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.